Literature DB >> 21764169

Outcome of 6 years of protocol use for preventing wrong site office surgery.

John Starling1, Brett M Coldiron2.   

Abstract

BACKGROUND: Patient safety is emerging as an integral part of the overall strategy to improve health care in the United States. Wrong site surgery is correctly noted to be a sentinel event and great efforts must be made to avoid it.
OBJECTIVE: We sought to determine the incidence of wrong site surgery after implementation of a preoperative protocol in patients presenting for treatment of skin cancer at a high-volume, Joint Commission-accredited, tertiary referral center for dermatologic surgery.
METHODS: A retrospective chart review was performed of 7983 cases performed on patients presenting for treatment of skin cancer in the office setting.
RESULTS: There were no cases of wrong site surgery. There were, however, 18 cases of failure to identify the original biopsy site (cancer site). LIMITATIONS: This was a retrospective study done at one cancer center.
CONCLUSION: Integration of a correct surgery site protocol into a daily patient care model is a useful step in preventing occurrences of wrong site dermatologic surgery.
Copyright © 2011 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21764169     DOI: 10.1016/j.jaad.2011.05.011

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  2 in total

Review 1.  Preventing complications in dermatologic surgery: Presurgical concerns.

Authors:  Allen G Strickler; Payal Shah; Shirin Bajaj; Richard Mizuguchi; Rajiv I Nijhawan; Mercy Odueyungbo; Anthony Rossi; Désirée Ratner
Journal:  J Am Acad Dermatol       Date:  2021-01-23       Impact factor: 15.487

2.  Incidence of Wrong-Site Surgery List Errors for a 2-Year Period in a Single National Health Service Board.

Authors:  Alistair Geraghty; Lorna Ferguson; Craig McIlhenny; Paul Bowie
Journal:  J Patient Saf       Date:  2020-03       Impact factor: 2.243

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.